Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
Get this delivered to your inbox, and more info about our products and services.
BioAge Labs' novel obesity treatment could boost the biotechnology company's stock, the Wall Street bank says.
The investment firm initiated coverage of the biopharma stock at a outperform rating.
The investment bank upgraded the pharma stock to overweight from equal weight.
Options trader Tony Zhang breaks down this call vertical trade on a pharma stock.
Tony Zhang breaks down how to trade this stock using options.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
